MDM2 is an inclusion eligibility criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and retinoblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and retinoblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCN is an inclusion eligibility criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and retinoblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and retinoblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RB1 is an inclusion eligibility criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 status and retinoblastoma as inclusion criteria, 1 is no phase specified (1 open) [3].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and retinoblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and retinoblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TET2 is an inclusion eligibility criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and retinoblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].